Ribo Announces Phase 2 Clinical Trial Application for siRNA Therapeutics Targeting Thromboembolic Diseases
Suzhou Ribo Life Science (stock code 06938.HK) along with Ribocure Pharmaceuticals, collectively referred to as "Ribo", has made a significant announcement that they have submitted a Phase 2 clinical trial application (CTA) to the European Medicines Agency (EMA). This application is for RBD1119, a novel siRNA-based therapeutic agent designed for the treatment of coronary artery disease (CAD). The submission underscores Ribo's commitment to advancing innovative therapies aimed at treating thromboembolic conditions.
Coronary artery disease remains a leading cause of morbidity and mortality worldwide, primarily due to the development of atherosclerotic plaques and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of standard treatments, including antiplatelet agents and anticoagulants, patients suffering from stable CAD still face significant residual risks for thrombotic events, even when receiving optimized therapy. Furthermore, existing therapies are often limited by an increased risk of bleeding, complicating their effectiveness and long-term application in many patients.
Because of this, there exists a notable unmet medical need for novel antithrombotic approaches that can deliver effective and sustained protection against thrombosis while simultaneously offering a favorable safety profile, especially concerning bleeding risk.
Highlighting the importance of this development, Dr. Anders Gabrielsen, Chief Medical Officer at Ribo, expressed enthusiasm about moving their antithrombotic siRNA programs into the next phase of clinical development in Europe. He stated, "This milestone reflects our commitment to leveraging the full potential of RNA-based therapies to offer patients who are currently inadequately treated with anticoagulants an improved benefit-risk profile."
Ribo has been actively advancing several siRNA candidates across areas such as atrial fibrillation and venous thromboembolism, establishing a leading pipeline in anticoagulation and antithrombosis. The current application for CAD represents a crucial step in Ribo's ambitious program aimed at further developing oligonucleotide-based therapies to systematically tackle the underlying causes of thromboembolic diseases.
The implications of this clinical trial could be far-reaching, reshaping treatment paradigms and potentially leading to better clinical outcomes for patients at risk of thrombotic events. As Ribo continues to push the boundaries of therapeutic innovation, the focus remains on providing enhanced solutions to meet the urgent needs within the cardiology landscape.
In conclusion, Ribo's submission of the Phase 2 clinical trial application to the EMA signifies a pivotal moment in the company's journey and the broader fight against coronary artery disease. The potential benefits of these siRNA-based treatments could offer new hope for patients globally who are currently left vulnerable to the threats posed by thromboembolic conditions.
For more information, stay tuned for further updates on Ribo's exciting advances in siRNA therapies.
Coronary artery disease remains a leading cause of morbidity and mortality worldwide, primarily due to the development of atherosclerotic plaques and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of standard treatments, including antiplatelet agents and anticoagulants, patients suffering from stable CAD still face significant residual risks for thrombotic events, even when receiving optimized therapy. Furthermore, existing therapies are often limited by an increased risk of bleeding, complicating their effectiveness and long-term application in many patients.
Because of this, there exists a notable unmet medical need for novel antithrombotic approaches that can deliver effective and sustained protection against thrombosis while simultaneously offering a favorable safety profile, especially concerning bleeding risk.
Highlighting the importance of this development, Dr. Anders Gabrielsen, Chief Medical Officer at Ribo, expressed enthusiasm about moving their antithrombotic siRNA programs into the next phase of clinical development in Europe. He stated, "This milestone reflects our commitment to leveraging the full potential of RNA-based therapies to offer patients who are currently inadequately treated with anticoagulants an improved benefit-risk profile."
Ribo has been actively advancing several siRNA candidates across areas such as atrial fibrillation and venous thromboembolism, establishing a leading pipeline in anticoagulation and antithrombosis. The current application for CAD represents a crucial step in Ribo's ambitious program aimed at further developing oligonucleotide-based therapies to systematically tackle the underlying causes of thromboembolic diseases.
The implications of this clinical trial could be far-reaching, reshaping treatment paradigms and potentially leading to better clinical outcomes for patients at risk of thrombotic events. As Ribo continues to push the boundaries of therapeutic innovation, the focus remains on providing enhanced solutions to meet the urgent needs within the cardiology landscape.
In conclusion, Ribo's submission of the Phase 2 clinical trial application to the EMA signifies a pivotal moment in the company's journey and the broader fight against coronary artery disease. The potential benefits of these siRNA-based treatments could offer new hope for patients globally who are currently left vulnerable to the threats posed by thromboembolic conditions.
For more information, stay tuned for further updates on Ribo's exciting advances in siRNA therapies.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.